Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 20
Filter
Add more filters










Publication year range
1.
Biomed Pharmacother ; 146: 112559, 2022 Feb.
Article in English | MEDLINE | ID: mdl-35062057

ABSTRACT

The analysis concerned the comparison of the expression of membrane type matrix metalloproteinases genes in the blood and tissue of NSCLC patients during the course of the disease and comparison to the control group. Blood and neoplastic tissue taken from 45 patients diagnosed with non-small cell lung cancer was a research material. The expression level of MMP14, MMP15, MMP16 and MMP24 was evaluated by qPCR and the results were compared with controls. The expression of MMP14 and MMP24 before tumor removal surgery and 100 days after was lower than in the control group. Interestingly, one year after surgery the levels of expression of these genes were identical to those in the control group. This suggests that the expression of metalloproteinase genes changes in the course of cancer and that effective treatment results in the normalization of gene expression. Lower expression of MMP15 in the blood of patients with more advanced cancer disease was observed, confirming the suppressive nature of changes in the blood. It has also been demonstrated that higher expression of MMP14 and MMP15 in the tissue is associated with more advanced stage of disease development or more invasive nature of the lesion. There is a noticeable increase of expression level in the environment surrounding the tumor, while a lower can be observed in the blood. This may indicate that changes in the expression of metalloproteinases in cancer are much more complex than merely the tumor tissue, which may also account for the inadequacies of metalloproteinase inhibitors.


Subject(s)
Carcinoma, Non-Small-Cell Lung/genetics , Lung Neoplasms/genetics , Matrix Metalloproteinase 14/blood , Matrix Metalloproteinase 15/blood , Matrix Metalloproteinase 16/blood , Matrix Metalloproteinases, Membrane-Associated/blood , Carcinoma, Non-Small-Cell Lung/blood , Carcinoma, Non-Small-Cell Lung/mortality , Case-Control Studies , Female , Gene Expression Regulation , Humans , Kaplan-Meier Estimate , Lung Neoplasms/blood , Male
2.
Clin Lab ; 66(5)2020 May 01.
Article in English | MEDLINE | ID: mdl-32390382

ABSTRACT

BACKGROUND: There is increasing evidence that matrix metalloproteinase 14 (MMP-14) is involved in tumor progression and prognosis. MMP-14 exhibits different expression in patients with various cancers, suggesting that it may be considered as a potential prognostic biomarker for cancer. METHODS: Therefore, this meta-analysis was performed to elucidate the prognostic value and association of MMP-14 over-expression in several types of cancers. Eligible studies based on eligibility criteria from various online databases were searched. The pooled hazard ratios (HRs) with 95% confidence intervals (CIs) for overall survival (OS) were analyzed to determine the prognostic value of MMP-14 using STATA software 12.0. RESULTS: We identified sixteen applicable studies in this meta-analysis comprising 2,766 samples. Over-expression MMP-14 was significantly correlated with a poor overall survival (OS) outcome in multiple cancers (HR: 2.22; 95% CI: 1.72 - 2.87). Moreover, high levels of MMP-14 were markedly associated with tumor progression and metastasis (HR: 1.83; 95% CI: 1.36 - 2.46). MMP-14 expression was also associated with histological differentiation (OR: 0.37; 95% CI: 0.18 - 0.77). CONCLUSIONS: MMP-14 over-expression suggested aggressive biological behaviors and implied that MMP-14 may be a useful prognostic biomarker in human cancers.


Subject(s)
Biomarkers, Tumor/blood , Matrix Metalloproteinase 14/blood , Neoplasms , Humans , Neoplasms/diagnosis , Neoplasms/epidemiology , Neoplasms/mortality , Sensitivity and Specificity
3.
Immunology ; 160(2): 209-219, 2020 06.
Article in English | MEDLINE | ID: mdl-32149403

ABSTRACT

CD100 is an immune semaphorin constitutively expressed on T-cells. Matrix metalloproteinase (MMP) is an important mediator of membrane-bound CD100 (mCD100) cleavage to generate soluble CD100 (sCD100), which has immunoregulatory activity in immune cell responses. The aim of the study was to investigate the level and role of sCD100 and mCD100 in modulating CD8+ T-cell function in non-small cell lung cancer (NSCLC). sCD100 and MMP-14 levels in the serum and bronchoalveolar lavage fluid (BALF), and mCD100 expression on peripheral and lung-resident CD8+ T-cells were analysed in NSCLC patients. The ability to induce sCD100 and the effect of MMP-14 on mCD100 shedding for the regulation of non-cytolytic and cytolytic functions of CD8+ T-cells were also analysed in direct and indirect contact co-culture systems. NSCLC patients had lower serum sCD100 and higher mCD100 levels on CD8+ T-cells compared with healthy controls. BALF from the tumour site also had decreased sCD100 and increased mCD100 on CD8+ T-cells compared with the non-tumour site. Recombinant CD100 stimulation enhanced non-cytolytic and cytolytic functions of CD8+ T-cells from NSCLC patients, whereas blockade of CD100 receptor CD72 attenuated CD8+ T-cell activity. NSCLC patients had lower MMP-14 in the serum and in BALF from the tumour site. Recombinant MMP-14 mediated mCD100 shedding from CD8+ T-cell membrane, and led to promotion of CD8+ T-cell response in NSCLC patients. Overall, decreased MMP-14 resulted in insufficient CD100 shedding, leading to suppression of peripheral and lung-resident CD8+ T-cell activity in NSCLC.


Subject(s)
Antigens, CD/metabolism , CD8-Positive T-Lymphocytes/immunology , Carcinoma, Non-Small-Cell Lung/immunology , Lung Neoplasms/immunology , Matrix Metalloproteinase 14/metabolism , Semaphorins/metabolism , Adult , Aged , Antigens, CD/blood , Bronchoalveolar Lavage Fluid/chemistry , CD8-Positive T-Lymphocytes/metabolism , Carcinoma, Non-Small-Cell Lung/blood , Carcinoma, Non-Small-Cell Lung/pathology , Cell Line, Tumor , Cell Membrane/metabolism , Coculture Techniques , Female , Humans , Lung/pathology , Lung Neoplasms/blood , Lung Neoplasms/pathology , Lymphocyte Activation , Male , Matrix Metalloproteinase 14/blood , Middle Aged , Primary Cell Culture , Recombinant Proteins/metabolism , Semaphorins/blood , T-Lymphocyte Subsets/immunology , T-Lymphocyte Subsets/metabolism , Tumor Escape , Tumor Microenvironment/immunology
4.
Med Sci Monit ; 25: 7770-7783, 2019 Oct 17.
Article in English | MEDLINE | ID: mdl-31619663

ABSTRACT

BACKGROUND Our previous research revealed that membrane type 1-matrix metalloproteinase (MT1-MMP) is overexpressed and plays a crucial role in gastric cancer (GC) progression. Exosomes are important for GC carcinogenesis, and the exosomal contents are ideal biomarkers. However, the expression of exosomal MT1-MMP mRNA in serum and its potential significance in GC remains unclear. MATERIAL AND METHODS The expression of exosomal MT1-MMP mRNA in serum of patients with GC, chronic gastritis, or atypical hyperplasia, and healthy controls was detected using real-time quantitative RT-PCR. Serum CEA, CA19-9, and CA72-4 were also measured by electrochemiluminescence assay. RESULTS Exosomes were isolated and identified in serum, and serum exosomal MT1-MMP mRNA was found to be higher in patients with GC compared with healthy controls and patients with chronic gastritis or atypical hyperplasia (all P<0.05). Serum exosomal MT1-MMP mRNA was significantly correlated with tumor diameter, differentiation, Borrmann type, invasion depth, lymphatic metastasis, distal metastasis, and TNM stage. The AUC of exosomal MT1-MMP mRNA was 0.788 (95% CI: 0.714-0.850) with 63.9% sensitivity and 87.1% specificity, and was higher than that of CEA (0.655 (95% CI: 0.573-0.730)). The combination of 2 markers gave an AUC of 0.821 (95% CI: 0.750-0.878), which was better than with the individual marker. The sensitivity, specificity, and positive and negative predictive values were 75.6%, 83.9%, 94.7%, and 47.3%, respectively. Moreover, the multiple logistic regression model showed that tumor diameter, differentiation, invasion depth, and exosomal MT1-MMP mRNA were the risk factors for lymphatic metastasis in GC. CONCLUSIONS Our results characterized serum exosomal MT1-MMP mRNA in GC, providing a foundation for discovering serum exosomes-targeted biomarkers for GC diagnosis.


Subject(s)
Exosomes/genetics , Matrix Metalloproteinase 14/genetics , RNA, Messenger/blood , Stomach Neoplasms/enzymology , Adult , Antigens, Tumor-Associated, Carbohydrate/blood , Biomarkers, Tumor/blood , Biomarkers, Tumor/genetics , CA-19-9 Antigen/blood , Carcinoembryonic Antigen/blood , Disease Progression , Exosomes/metabolism , Female , Humans , Lymphatic Metastasis , Male , Matrix Metalloproteinase 14/blood , Middle Aged , RNA, Messenger/genetics , Stomach Neoplasms/blood , Stomach Neoplasms/genetics
5.
Talanta ; 205: 120142, 2019 Dec 01.
Article in English | MEDLINE | ID: mdl-31450394

ABSTRACT

We reported here two novel electrochemical impedance spectroscopy biosensors were developed for the first time for highly sensitive quantification of matrix metalloproteinase-14 (MMP-14) based on binding interaction between hemopexin-like domain (PEX) of MMP-14 (PEX-14) and its inhibitory peptides. Specific inhibitory peptides (IVSC or ISC) inhibiting homodimerization or heterodimerization of MMP-14 was first self assembled on the surface of gold electrode and blocked with 6-mercapto-1-hexanol on a gold electrode surface used as IVSC or ISC modified biosensor, respectively. IVSC modified biosensor can be used for detection of MMP-14 by using the direct IVSC-MMP-14 interaction inhibiting MMP-14 homodimerization as well as ISC modified biosensor for indirect detection of MMP-14 via PEX-14 mediated peptide-MMP-14 binding. The electron transfer resistance (Ret) of biosensor was monitored to measure MMP-14 using Fe(CN)63-/4- as probe. The increase of the Ret of the biosensors are linear with the concentration of MMP-14 in the range from 1 µg L-1 to 10 µg L-1 with detection limit of 0.19 µg L-1 for IVSC modified biosensor and 0.1 ng L-1 to 50 ng L-1 with detection limit of 7 ng L-1 for ISC modified biosensor. This work demonstrates that probing the interaction between peptide inhibitor and PEX of MMPs represents a novel approach to assess MMPs-mediated cancer dissemination.


Subject(s)
Biosensing Techniques/methods , Dielectric Spectroscopy , Matrix Metalloproteinase 14/analysis , Matrix Metalloproteinase 14/chemistry , Peptides/pharmacology , Protein Multimerization/drug effects , Electrochemistry , Electrodes , Gold/chemistry , Limit of Detection , Matrix Metalloproteinase 14/blood , Protein Domains , Protein Structure, Quaternary
6.
Ann Vasc Surg ; 57: 201-209, 2019 May.
Article in English | MEDLINE | ID: mdl-30684618

ABSTRACT

BACKGROUND: Intimal hyperplasia (IH) is the most common indicator for secondary intervention in peripheral vascular disease. Matrix metalloproteinases (MMPs) play a role in IH development due to their degradation of the extracellular matrix. Doxycycline (Doxy), a member of the tetracycline family of antibiotics, is a potent MMP inhibitor. We have previously shown that Doxy inhibits MMP activity and vascular smooth muscle cell migration in vitro. We hypothesized that Doxy would decrease MMP activity in vivo and inhibit the development of IH in a rodent model of vascular injury. METHODS AND RESULTS: Doxy (400 mg/pellet) was delivered by a slow-release pellet implanted 3 days prior to or at the time of balloon angioplasty (BA) of the common carotid artery in female rats. At 14 days post-BA, intima-to-media (I:M) ratios were 0.77 ± 0.21 and 1.04 ± 0.32 in the Doxy treated groups, respectively, compared to 1.25 ± 0.26 in the control group (P = not significant; n = 3). Additionally, the tested dose of Doxy in either group had no inhibitory effect on membrane type 1-MMP or MMP-2 tissue levels, as measured by immunohistochemistry, or on systemic levels of MMP, as measured by total MMP serum levels using enzyme-linked immunosorbent assay. At 14 days post-BA, VSMC proliferation in the injured artery was increased to Doxy treatment prior to and at the time of surgery (23.5 ± 3.4 and 27.2 ± 3.9%, respectively), compared to control (11.4 ± 0.4%; n = 3), as measured by proliferating cellular nuclear antigen immunostaining. CONCLUSIONS: In our in vivo model of vascular injury, systemic Doxy administration prior to or at the time of vascular injury does not significantly hinder the progression of IH development. Additional doses and routes of administration could be examined in order to correlate therapeutic serum levels of Doxy with effective MMP inhibition in serum and arterial tissue. However, alternative drug delivery systems are needed in order to optimize therapeutic administration of targeted MMP inhibitors for the prevention of IH development.


Subject(s)
Angioplasty, Balloon/adverse effects , Cardiovascular Agents/administration & dosage , Carotid Artery Injuries/drug therapy , Doxycycline/administration & dosage , Muscle, Smooth, Vascular/drug effects , Myocytes, Smooth Muscle/drug effects , Neointima , Animals , Carotid Artery Injuries/blood , Carotid Artery Injuries/enzymology , Carotid Artery Injuries/pathology , Carotid Artery, Common/drug effects , Carotid Artery, Common/enzymology , Carotid Artery, Common/pathology , Cell Proliferation/drug effects , Disease Models, Animal , Female , Hyperplasia , Matrix Metalloproteinase 14/blood , Matrix Metalloproteinase 2/blood , Muscle, Smooth, Vascular/enzymology , Muscle, Smooth, Vascular/injuries , Muscle, Smooth, Vascular/pathology , Myocytes, Smooth Muscle/enzymology , Myocytes, Smooth Muscle/pathology , Rats, Sprague-Dawley
7.
PLoS One ; 13(12): e0208800, 2018.
Article in English | MEDLINE | ID: mdl-30532247

ABSTRACT

Matrix metalloproteinases (MMPs), endopeptidases with diverse biochemical functions, can promote cancer cell invasion and metastasis by degrading the extracellular matrix. A high matrix metalloproteinase-14 (MMP-14) expression in gastric cancer tissue has been associated with metastasis and poor prognosis. To further understand this association, we investigated serum MMP-14 as a biomarker in gastric cancer patients. The patient cohort consisted of 240 gastric adenocarcinoma patients who underwent surgery at Helsinki University Hospital, Finland, between 2000 and 2009. We determined the soluble MMP-14 serum levels using an enzyme-linked immunosorbent assay. We then calculated the associations between serum levels and clinicopathologic variables using the Mann-Whitney U-test or the Kruskal-Wallis test. We constructed survival curves using the Kaplan-Meier method and calculating the hazard ratios using the Cox proportional hazard model. We revealed a positive association between a high serum MMP-14 level and stages III-IV (p = 0.029), and between a high serum MMP-14 and distant metastasis (p = 0.022). Patients with a low serum MMP-14 had a 5-year disease-specific survival of 49.2% (95% confidence interval [CI] 45.5-52.9), whereas patients with a high serum MMP-14 had a 5-year survival of 22.1% (95% CI 15.2-29.0; p = 0.001). High serum MMP-14 was a statistically significant prognostic factor among patients with an intestinal type of cancer (hazard ratio [HR] 3.54; 95% CI 1.51-8.33; p = 0.004), but not among patients with a diffuse type. The serum MMP-14 level remained an independent prognostic factor in our multivariate survival analysis (HR 1.55; 95% CI 1.02-2.35; p = 0.040). This study indicates for the first time that high serum soluble MMP-14 levels in gastric cancer serves as a marker for a poor prognosis, possibly indicating the presence of distant metastases.


Subject(s)
Adenocarcinoma , Biomarkers, Tumor/blood , Matrix Metalloproteinase 14/blood , Neoplasm Proteins/blood , Stomach Neoplasms , Adenocarcinoma/blood , Adenocarcinoma/mortality , Adenocarcinoma/pathology , Aged , Disease-Free Survival , Female , Finland/epidemiology , Follow-Up Studies , Humans , Male , Middle Aged , Neoplasm Metastasis , Retrospective Studies , Stomach Neoplasms/blood , Stomach Neoplasms/mortality , Stomach Neoplasms/pathology , Survival Rate
8.
Dis Model Mech ; 10(10): 1253-1260, 2017 10 01.
Article in English | MEDLINE | ID: mdl-28993312

ABSTRACT

Levels of matrix metalloproteases (MMPs) can be differentially regulated in response to injury or neurological diseases. For instance, it is known that selective and short-term inhibition of MMP-14, a membrane-type 1 MMP, accelerates axon regeneration. Because axon growth and regeneration is impaired in familial amyloidotic polyneuropathy (FAP), a neurodegenerative disorder characterized by misfolding and deposition of mutant transthyretin (TTR) in the peripheral nervous system (PNS), we presently investigated the expression levels and the potential role for MMP-14 in this condition. By using cell culture studies, a mouse model of disease and human clinical samples, we observed that MMP-14: (i) is overexpressed in FAP nerves, correlating with TTR deposition; (ii) is upregulated in sciatic nerves from a preclinical transgenic mouse model, increasing with TTR deposition; (iii) levels in the PNS and plasma are rescued upon treatment of mice with anakinra or TTR siRNA, drugs acting over the IL-1 signaling pathway or TTR liver synthesis, respectively; (iv) increases in Schwann cells upon incubation with amyloid-like aggregates; and, finally, (v) is increased in plasma of FAP patients, correlating with disease progression. These results highlight the relevance of MMP-14 in the pathophysiology of FAP, suggesting not only a potential role for this molecule as a novel biomarker for therapy follow up, but also as a new potential therapeutic target.


Subject(s)
Amyloid Neuropathies, Familial/enzymology , Matrix Metalloproteinase 14/blood , Nerve Degeneration , Sciatic Nerve/enzymology , Sural Nerve/enzymology , Amyloid Neuropathies, Familial/blood , Amyloid Neuropathies, Familial/pathology , Amyloid Neuropathies, Familial/therapy , Animals , Case-Control Studies , Cells, Cultured , Disease Models, Animal , Enzyme Induction , Humans , Interleukin 1 Receptor Antagonist Protein/pharmacology , Liver/metabolism , Matrix Metalloproteinase 14/biosynthesis , Matrix Metalloproteinase 14/genetics , Mice, 129 Strain , Mice, Transgenic , Prealbumin/genetics , Prealbumin/metabolism , RNA Interference , RNAi Therapeutics , Schwann Cells/metabolism , Schwann Cells/pathology , Sciatic Nerve/drug effects , Sciatic Nerve/pathology , Signal Transduction , Sural Nerve/pathology , Time Factors
9.
Environ Toxicol Pharmacol ; 53: 199-205, 2017 Jul.
Article in English | MEDLINE | ID: mdl-28654832

ABSTRACT

Lead (Pb), cadmium (Cd) and manganese (Mn) have many potential adverse health effects in vitro and in animal models of clinical toxicity. The current study investigated the dyslipidaemic and oxidative stress effects of chronic low-dose oral exposure to Pb, Cd and Mn and the combination (Pb+Cd+Mn) in rats for 15 weeks. Chronic exposure to the metals did not significantly (P>0.05) alter serum lipid profiles. However, the atherogenic index decreased by 32.2% in the Pb+Cd+Mn group, relative to the control. The triglyceride/high-density lipoprotein cholesterol ratio decreased by 39.4% in the Pb+Cd+Mn group, relative to the control, and elevated by 81.8, 94.8 and 20.8%, relative to the Pb, Cd and Mn groups, respectively. While the serum concentrations of malondialdehyde significantly increased in the Mn and Pb+Cd+Mn groups, that of glutathione peroxidase-1 decreased in the Pb+Cd+Mn group, and metallothionein-1 and zinc concentrations markedly decreased in all the metal treatment groups. The results suggest that long-term exposure of rats to Pb+Cd+Mn may result in hypolipidaemia, mediated via oxidative stress and metal interactions. Individuals who are constantly exposed to environmentally relevant levels of the metals may be at risk of hypolipidaemia.


Subject(s)
Cadmium/toxicity , Dyslipidemias/chemically induced , Lead/toxicity , Manganese/toxicity , Oxidative Stress/drug effects , Animals , Cadmium/blood , Cholesterol/blood , Dyslipidemias/blood , Glutathione Peroxidase/blood , Lead/blood , Male , Malondialdehyde/blood , Manganese/blood , Matrix Metalloproteinase 14/blood , Rats, Wistar , Triglycerides/blood , Glutathione Peroxidase GPX1
10.
J BUON ; 22(2): 519-523, 2017.
Article in English | MEDLINE | ID: mdl-28534379

ABSTRACT

PURPOSE: To investigate the therapeutic effects of different doses of 125I radioactive particle brachytherapy on oral cancer. METHODS: Between September 2012 and September 2015, 78 patients with oral cancer who received 125I radioactive particle brachytherapy for the first time in our hospital were enrolled in this study. Patients were divided into high dose (≥3) and low dose (<3) groups. The treatment outcome, serum tumor marker levels and the expression levels of autophagy and apoptotic genes in tumor cells were compared between groups. RESULTS: Complete remission (CR)+partial remission (PR) ratio in the high dose group was significantly higher than that of the low dose group. Stable disease (SD)+ progressive disease (PD) ratio was significantly lower in the high dose group. The serum levels of TSGF, SCCA, CEA, CA125, CA15.3, CA19.9 and PSA oral cancer markers were significantly lower than those of the low dose group. In the high dose group, the expression levels of Beclin-1 and MAP1LC3 (autophagic genes) mRNAs were significantly higher than those of the low dose group, while the expression levels of EMMPRIN and MMP-14 (invasive genes) mRNAs were significantly lower in the high dose group. Also survival rates in the responsive patients were significantly better in comparison to non-responsive patients. CONCLUSION: High dose particle brachytherapy with radioactive 125I is a safe and effective treatment and its clinical results were more beneficial than the low dose therapy.


Subject(s)
Carcinoma/radiotherapy , Iodine Radioisotopes/therapeutic use , Mouth Neoplasms/radiotherapy , Adult , Aged , Antigens, Neoplasm/blood , Basigin/blood , Biomarkers, Tumor/blood , Brachytherapy/methods , CA-125 Antigen/blood , CA-19-9 Antigen/blood , Carcinoma/blood , Carcinoma/metabolism , Female , Humans , Male , Matrix Metalloproteinase 14/blood , Middle Aged , Mouth Neoplasms/blood , Mouth Neoplasms/metabolism , Radiometry/methods , Survival Rate
11.
J Immunol ; 193(3): 1344-52, 2014 Aug 01.
Article in English | MEDLINE | ID: mdl-24973455

ABSTRACT

Proteolytic shedding of ligands for the NK group 2D (NKG2D) receptor is a strategy used by tumors to modulate immune recognition by NK cells and cytotoxic T cells. A number of metalloproteases, especially those of the A disintegrin and metalloprotease (ADAM) family, can mediate NKG2D ligand cleavage and this process can be modulated by expression of the thiol isomerase ERp5. In this article, we describe that an increased shedding of the NKG2D ligand MICA is observed postinfection with several strains of human CMV due to an enhanced activity of ADAM17 (TNF-α converting enzyme) and matrix metalloprotease 14 caused by a reduction in the expression of the endogenous inhibitor of metalloproteases tissue inhibitors of metalloproteinase 3 (TIMP3). This decrease in TIMP3 expression correlates with increased expression of a cellular miRNA known to target TIMP3, and we also identify a human CMV-encoded microRNA able to modulate TIMP3 expression. These observations characterize a novel viral strategy to influence the shedding of cell-surface molecules involved in immune response modulation. They also provide an explanation for previous reports of increased levels of various ADAM17 substrates in the serum from patients with CMV disease. Consistent with this hypothesis, we detected soluble MICA in serum of transplant recipients with CMV disease. Finally, these data suggest that it might be worthwhile to prospectively study ADAM17 activity in a larger group of patients to assay whether this might be a useful biomarker to identify patients at risk for development of CMV disease.


Subject(s)
Cytomegalovirus Infections/immunology , Down-Regulation/immunology , Gene Expression Regulation, Viral/immunology , Histocompatibility Antigens Class I/metabolism , MicroRNAs/genetics , Tissue Inhibitor of Metalloproteinase-3/antagonists & inhibitors , Tissue Inhibitor of Metalloproteinase-3/biosynthesis , Cell Line, Tumor , Cytomegalovirus/genetics , Cytomegalovirus/immunology , Cytomegalovirus Infections/enzymology , Cytomegalovirus Infections/genetics , Down-Regulation/genetics , Histocompatibility Antigens Class I/blood , Humans , Matrix Metalloproteinase 14/blood , Matrix Metalloproteinase 14/metabolism , MicroRNAs/biosynthesis , Primary Cell Culture , Substrate Specificity/genetics , Substrate Specificity/immunology , Tissue Inhibitor of Metalloproteinase-3/blood , Up-Regulation/genetics , Up-Regulation/immunology
12.
Cancer Res ; 73(8): 2457-2467, 2013 Apr 15.
Article in English | MEDLINE | ID: mdl-23423981

ABSTRACT

Most patients with ovarian cancer are diagnosed late in progression and often experience tumor recurrence and relapses due to drug resistance. Surface expression of matrix metalloprotease (MMP)-14 on ovarian cancer cells stimulates a tumor-stromal signaling pathway that promotes angiogenesis and tumor growth. In a cohort of 92 patients, we found that MMP-14 was increased in the serum of women with malignant ovarian tumors. Therefore, we investigated the preclinical efficacy of a MMP-14 monoclonal antibody that could inhibit the migratory and invasive properties of aggressive ovarian cancer cells in vitro. MMP-14 antibody disrupted ovarian tumor-stromal communication and was equivalent to Avastin in suppressing blood vessel growth in mice harboring Matrigel plugs. These effects on angiogenesis correlated with downregulation of several important angiogenic factors. Furthermore, mice with ovarian cancer tumors treated with anti-MMP-14 monotherapy showed a marked and sustained regression in tumor growth with decreased angiogenesis compared with immunoglobulin G (IgG)-treated controls. In a model of advanced peritoneal ovarian cancer, MMP-14-dependent invasion and metastasis was effectively inhibited by intraperitoneal administration of monoclonal MMP-14 antibody. Together, these studies provide a preclinical proof-of-concept for MMP-14 targeting as an adjuvant treatment strategy for advanced ovarian cancer.


Subject(s)
Antibodies, Monoclonal/pharmacology , Matrix Metalloproteinase 14/metabolism , Matrix Metalloproteinase Inhibitors/pharmacology , Neovascularization, Pathologic/metabolism , Ovarian Neoplasms/metabolism , Ovarian Neoplasms/pathology , Tumor Burden/drug effects , Animals , Antibodies, Monoclonal/administration & dosage , Antineoplastic Agents/pharmacology , Biomarkers, Tumor/blood , Cell Line, Tumor , Cell Movement/drug effects , Disease Models, Animal , Docetaxel , Female , Human Umbilical Vein Endothelial Cells/drug effects , Human Umbilical Vein Endothelial Cells/metabolism , Humans , Matrix Metalloproteinase 14/blood , Matrix Metalloproteinase 14/genetics , Matrix Metalloproteinase Inhibitors/administration & dosage , Mice , Mice, Nude , Neoplasm Invasiveness , Neoplasm Metastasis , Neovascularization, Pathologic/genetics , Ovarian Neoplasms/genetics , Taxoids/pharmacology , Tumor Microenvironment/drug effects , Tumor Microenvironment/genetics , Xenograft Model Antitumor Assays
13.
Forensic Sci Int ; 220(1-3): 12-8, 2012 Jul 10.
Article in English | MEDLINE | ID: mdl-22306189

ABSTRACT

Forensic identification of body fluids is a crucial aspect of the discipline. To date, there are no robust tests to make a distinction between menstrual blood and peripheral blood. Past techniques have fallen short of producing clear and consistent results while present mRNA techniques are still in their infancy. The aim of this study was to develop of an accurate and rapid immunoassay based identification method. Three different targets were evaluated: matrix metalloproteinase 14 (MMP14), oestrogen receptor α (ERα), and fibrinogen. Cellular or membrane bound antigens were analyzed using immunocytochemical staining while soluble antigens were analyzed by indirect ELISA. Results showed that ERα and MMP14 are present in the endometrial cells of menstrual blood but absent in peripheral blood. At a total protein concentration of 10 µg/mL or lower, fibrinogen was detected in menstrual blood but absent in peripheral. If evaluated on a larger scale, immunoassays may prove to be beneficial in discriminating menstruum and peripheral blood.


Subject(s)
Endometrium/cytology , Estrogen Receptor alpha/blood , Fibrinogen/analysis , Matrix Metalloproteinase 14/blood , Menstruation/blood , Enzyme-Linked Immunosorbent Assay , Estrogen Receptor alpha/immunology , Female , Fibrinogen/immunology , Fluorescent Antibody Technique, Direct , Fluorescent Dyes , Forensic Pathology/methods , Humans , Immunohistochemistry , Indoles , Matrix Metalloproteinase 14/immunology
14.
Mol Biol (Mosk) ; 45(2): 376-81, 2011.
Article in Russian | MEDLINE | ID: mdl-21634125

ABSTRACT

A new algorithm has been developed for bioinformatics search of putative serum markers of cancer, which includes: 1) identification of microRNAs that are most often and most significantly overexpressed in tumors; 2) selection of mRNA targets regulated by microRNAs; 3) identification of mRNA targets encoding secreted proteins; 4) comparative analysis of mRNA transcription levels in normal and tumor tissues. Application of the algorithm led to discovery of seven putative serum markers of colon cancer: ADAMTS14, ANGPT2, CCL7, DEFA5, MMP11, MMP14, and PLAU. Experiments demonstrated that production of two out of seven proteins (MMP14 and DEFA5) is significantly increased in colon tumors vs. normal samples.


Subject(s)
Biomarkers, Tumor/blood , Computational Biology/methods , MicroRNAs/genetics , Neoplasms/blood , Algorithms , Biomarkers, Tumor/genetics , Databases, Genetic , Defensins/blood , Defensins/genetics , Gene Expression Profiling , Humans , Matrix Metalloproteinase 14/blood , Matrix Metalloproteinase 14/genetics , Neoplasms/diagnosis
15.
Folia Histochem Cytobiol ; 48(1): 101-3, 2010 Jan 01.
Article in English | MEDLINE | ID: mdl-20529824

ABSTRACT

UNLABELLED: Different types of matrix metalloproteinases, including membrane type 1 matrix metalloproteinase (MT1-MMP/MMP-14) can be easily detected in biological fluids and therefore may be contemplated as putative tumor markers. Although increased activity of MT1-MMP/MMP-14 have already been found in breast cancer, little is known about its circulating levels. The aim of the present study was therefore to evaluate serum levels of active form of membrane type 1 matrix metalloproteinase (MT1-MMP/MMP-14). A novel type of activity enzyme-linked immunosorbent assay was used to detect serum levels of MT1-MMP/MMP-14 in 18 patients with invasive ductal breast cancer and 11 healthy controls. In the breast cancer group of patients MT1-MMP/MMP-14 mean (+/-SD) concentration was 16.91+/-5.87 ng/ml which was significantly higher (p<0.0001) than the mean values obtained for the control i.e. 8.55+/-1.66 ng/ml. CONCLUSIONS: Higher levels of soluble form of MT1-MMP/MMP-14 could play a role in invasiveness and metastasis of breast cancer. Whether or not it has a potential as biochemical marker remains to be determined.


Subject(s)
Breast Neoplasms/blood , Breast Neoplasms/enzymology , Matrix Metalloproteinase 14/blood , Adult , Aged , Carcinoma, Ductal, Breast/blood , Carcinoma, Ductal, Breast/enzymology , Case-Control Studies , Female , Humans , Middle Aged
16.
Acta Biochim Pol ; 56(4): 717-22, 2009.
Article in English | MEDLINE | ID: mdl-19997654

ABSTRACT

In the pathogenesis of dilated cardiomyopathy (DCM) in Emery-Dreifuss muscular dystrophy (EDMD) matrix metalloproteinases (MMPs) are supposed to be involved and may have diagnostic/prognostic value. Serum levels of MT1-MMP, MMP-2 and MMP-9 were quantified by ELISA and zymography in 22 EDMD patients and 15 age-matched controls. In the autosomal-dominant EDMD MMP-2 and MT1-MMP were increased in all cases, and MMP-9 was increased in two of the eight examined patients. In the X-linked EDMD MMP-2 expression was increased in all the cases, MMP-9 level was elevated in 3 of the 14 cases, and MT1-MMP was decreased in eight of these patients. There was no evident correlation between the MMPs level and the different cardiac parameters including left-ventricular end-diastolic diameter, left atrial diameter and left ventricular ejection fraction in either form of EDMD. The presented results indicate that a changed level of matrix metalloproteinases, especially that of MMP-2 in serum, may be of value for detection of cardiac involvement in EDMD patients, especially in those patients with no evident subjective cardiac symptoms. Further follow-up studies of MMPs are needed to check if their determination is of value for monitoring of the progression of atrial/ventricular dilatation. MMPs determinations may also be useful for monitoring DCM treatment by synthetic MMPs inhibitors.


Subject(s)
Cardiomyopathy, Dilated/enzymology , Matrix Metalloproteinase 14/blood , Matrix Metalloproteinase 2/blood , Matrix Metalloproteinase 9/blood , Muscular Dystrophy, Emery-Dreifuss/enzymology , Adolescent , Adult , Female , Humans , Male , Middle Aged , Muscular Dystrophy, Emery-Dreifuss/blood
18.
Clin Chim Acta ; 390(1-2): 44-8, 2008 Apr.
Article in English | MEDLINE | ID: mdl-18230350

ABSTRACT

BACKGROUND: Recently, membrane type matrix metalloproteinase-1 (MT1-MMP) was found to participate in bone metabolism. We investigated the relationship between serum MT1-MMP and bone mineral density (BMD) as well as bone metabolic markers in 206 Chinese postmenopausal women aged 43-80 years. METHODS: Western analysis and ELISA were performed to detect serum soluble MT1-MMP levels. BMD was measured by dual energy X-ray absorptiometry (DXA). Serum alkaline phosphatase (BAP) and N-telopeptides of type I collagen (NTX) were assayed using ELISA. RESULTS: We found that soluble MT1-MMP abundantly existed in human serum as protein lack of transmembrane domain. Serum MT1-MMP levels were detectable in all participants and the range of value was 221.2-863.0 ng/ml (435.6+/-98.2 ng/ml). We found a significant negative weaker correlation between MT1-MMP and BMD at lumbar spine, total hip (Thip), and femoral neck (FN) (all P<0.05). After adjustment for age and BMI, the correlation with BMD at FN and Thip disappeared (all P>0.05). Multiple linear stepwise regression analysis showed that MT1-MMP was not a determinant factor for BMD. The significant positive correlations between MT1-MMP and BAP, NTX were found, and remained significant after adjustment for age and BMI (all P<0.05). Moreover, serum MT1-MMP, BAP, and NTX decreased in response to alendronate therapy. CONCLUSION: Circulating MT1-MMP and bone turnover markers are correlated, and serum MT1-MMP levels may rise with increase in bone turnover.


Subject(s)
Biomarkers/blood , Bone Density , Matrix Metalloproteinase 14/blood , Postmenopause , Absorptiometry, Photon , Adult , Aged , Aged, 80 and over , Blotting, Western , Enzyme-Linked Immunosorbent Assay , Female , Humans , Middle Aged , Solubility
19.
Br J Haematol ; 138(2): 221-30, 2007 Jul.
Article in English | MEDLINE | ID: mdl-17593030

ABSTRACT

When stimulated in vitro, human platelets release matrix metalloproteinase-2 (MMP-2) that, in turn, potentiates platelet activation. The present study investigated if MMP-2 is released from activated platelets in vivo in humans and whether aspirin inhibits this release. MMP-2 levels were measured by zymography, immunoblotting, flow-cytometry and an activity assay system, in plasma prepared from blood emerging from a skin wound inflicted for the measurement of the bleeding time (shed blood) and simultaneously from venous blood in 27 healthy human volunteers. In a subgroup, the same measurements were carried out before and 1 h after aspirin intake. MMP-2 was significantly higher in shed blood than in venous blood and increased progressively, consistent with ongoing platelet activation. A significant correlation was evident between platelet number and MMP-2 in shed blood; platelet MMP-2 content in shed blood was lower than that of platelets in venous blood. The level of active MMP-2 released by activated platelets in vivo was within the range of concentrations that potentiate platelet activation. Aspirin did not reduce MMP-2 release in vivo. In conclusion, MMP-2 is released from platelets in vivo in humans at a localised site of vessel wall damage in amounts sufficient to potentiate platelet aggregation; aspirin does not reduce this release.


Subject(s)
Aspirin/administration & dosage , Blood Platelets/metabolism , Fibrinolytic Agents/administration & dosage , Hemorrhage/metabolism , Matrix Metalloproteinase 2/blood , Administration, Oral , Adult , Bleeding Time , Blood Platelets/drug effects , Female , Flow Cytometry/methods , Humans , Male , Matrix Metalloproteinase 14/blood , Middle Aged , Platelet Activation/physiology , Platelet Aggregation/physiology , Platelet Aggregation Inhibitors/administration & dosage , Platelet Count , Tissue Inhibitor of Metalloproteinase-2/blood
20.
Exp Biol Med (Maywood) ; 232(5): 629-37, 2007 May.
Article in English | MEDLINE | ID: mdl-17463159

ABSTRACT

Matrix metalloproteinases (MMPs) are a family of neutral proteinases that are involved in tissue remodeling by mediating degradation of extracellular matrix components in both physiology and pathology. As MMPs appear to play a key role in the degradation of cartilage matrix in the progression of arthritic disease, MMPs are considered as potential therapeutic targets. The effect of chondroitin sulfate A (CSA) on MMPs in type II collagen-induced experimental arthritis was studied. The anti-arthritic effect of CSA was evidenced by a decrease in marker activities like lysosomal beta-hexosaminidase and beta-glucuronidase. Arthritic animals showed significantly higher activity of MMP2 and MMP9 and increased levels of other MMPs, including MMP3 and MT-1 MMP in cartilage and serum. Treatment with CSA significantly decreased the activity of MMPs, particularly MMP9 in serum and synovial effusate and cartilage. The effect of CSA was further studied by fragmenting CSA into low-molecular-weight oligosaccharides. The oligosaccharide-treated animals showed considerably lower MMP activity (particularly MMP9) compared with arthritic controls. The CSA (and the oligosaccharides derived from it) not only reduced the activity of MMPs but also decreased the protein level expression of MMPs, indicating that the production of MMPs is affected. These results indicate that the antiarthritic effect of CSA involves down-regulation of MMPs, which are critically involved in the progression of arthritic disease.


Subject(s)
Arthritis, Experimental/prevention & control , Collagen Type II/toxicity , Glycosaminoglycans/pharmacology , Matrix Metalloproteinases/metabolism , Animals , Arthritis, Experimental/chemically induced , Arthritis, Experimental/enzymology , Chondroitin Sulfates/chemistry , Chondroitin Sulfates/pharmacology , Enzyme-Linked Immunosorbent Assay , Glycosaminoglycans/chemistry , Male , Matrix Metalloproteinase 14/blood , Matrix Metalloproteinase 14/metabolism , Matrix Metalloproteinase 2/blood , Matrix Metalloproteinase 2/metabolism , Matrix Metalloproteinase 3/blood , Matrix Metalloproteinase 3/metabolism , Matrix Metalloproteinase 9/blood , Matrix Metalloproteinase 9/metabolism , Matrix Metalloproteinases/blood , Oligosaccharides/pharmacology , Rats , Rats, Wistar
SELECTION OF CITATIONS
SEARCH DETAIL
...